Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis

Pediatric Pulmonology

Volumn 46, Issue 4, 2011, Pages 401-408

  Coates, Allan L ^a   Denk, Oliver ^b   Leung, Kitty ^a   Ribeiro, Nancy ^a   Chan, Jeffrey ^a   Green, Maria ^a   Martin, Sean ^a   Charron, Martin ^a   Edwardes, Michael ^c   Keller, Manfred ^b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b Pari Pharma GmbH   (Germany)

^c Everest Clinical Research Services   (Canada)

Author keywords

Drug adherence; Inhalation; Lung deposition; Rapid delivery; Tobramycin

Indexed keywords

PENTETATE TECHNETIUM TC 99M; TOBRAMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; MALE; MEDICAL NEBULIZER; PRIORITY JOURNAL; SCHOOL CHILD; SURGICAL EQUIPMENT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; HUMANS; LUNG; MALE; NEBULIZERS AND VAPORIZERS; PATIENT PREFERENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952754504     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21376     Document Type: Article

References (30)

1. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailablility of aerosolized tobramycin in cystic fibrosis. Chest 2002;122:219-226. (Pubitemid 34754166)
2. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-1746. (Pubitemid 23170123)
3. Ramsey BW, Pepe MS, Quan JF, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz DS, Bowman CM, Marshall BC, Marshall S, Smith AL. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30. (Pubitemid 29024680)
4. MacLusky IB, Gold R, Corey ML, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7:42-48.
5. Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis: what gets in the way. J Pediatr Psychol 2006;31:846-858. (Pubitemid 44310212)
6. Abbott J, Dodd M, Webb K. Ways of coping with cystic fibrosis: implications for treatment adherence. Disabil Rehabil 2001;23:315-324. (Pubitemid 32440331)
7. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamycin in cystic fibrosis. Am Rev Respir Dis 1987;136:1445-1449. (Pubitemid 18030280)
8. Knoch M, Keller M. The customized electronic nebulizer, eFlow: a new category of liquid aerosol delivery system. Expert Opin Drug Deliv 2005;2:377-390. (Pubitemid 41130890)
9. 99mTc-DTPA from delivery systems with very different delivery times. J Aerosol Med 2007; 20:320-330.
10. Coates AL, MacNeish CF, Dinh L, Rollin T, Gagnon S, Ho SL, Lands LC. Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition. J Aerosol Med 2000;13:169-178.
11. Tservistas M, Balcke A, Stempfle P, Reul K,Walther E, Keller M. Nebulizer systems and formulation characteristics: two factors affecting in vitro inhaler system performance for cystic fibrosis treatment. Drug Deliv Lung 2003;14:176-179.
12. Marple VA, Olson BA, Santhanakrishnan K, Roberts DL, Mitchell JP, Hudson-Curtis BL. Calibration of the archival next generation pharmaceutical impactor (NGI) at 15 L/min. Drug Deliv Lung 2003;14:37-40.
13. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187. (Pubitemid 29036522)
14. Miller MR, Hankinson JL, Brusasco V, Burgos F, Casaburi R, Coates AL, Crapo RO, Enright PL, van der Grinten CP, Gustafsson PM, Jensen RL, Johnson DC, MacIntyre NR, McKay RT, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger JK. Standarisation of spirometry. Eur Respir J 2005;26:319-338.
15. Coates AL, MacNeish CF, Lands LC, Meisner D, Kelemen S, Vadas EB. A comparison of the availability of tobramycin for inhalation from vented versus unvented nebulizers. Chest 1998;113:951-956. (Pubitemid 28216437)
16. Coates AL, Green M, Leung K, Chan J, Ribeiro N, Louca E, Ratjen F, Charron M, Tservistas M, Keller M. Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project. Pediatr Pulmonol 2008;43:753-759.
17. Macey DJ, Marshall R. Absolute quantitation of radiotracer uptake in the lungs using a gamma camera. J Nucl Med 1982;23:731-735.
18. Smaldone GC, Fuhrer J, Steigbigel RT, McPeck M. Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1991;143:727-737.
19. Gagnadoux F, Diot P, Marchand S, Thompson R, Dieckman K, Lemarié E, Varaigne F, Maurage C, Baulieu JL, Rolland JC. Déposition pulmonaire des aérosols de colistine dans la mucoviscidose: Comparaison d'un nébuliseur ultrasonique et d'un pneumatique. Rev Mal Resp 1996;13:55-60. (Pubitemid 26157815)
20. Laube BL, Jashnani R, Dalby RN, Zeitlin PL. Targeting aerosol deposition in patients with cystic fibrosis: effects of alteration in particle size and inspiratory flows. Chest 2000;118:1069-1076.
21. Coates AL, MacNeish CF, Allen PD, Ho SL, Lands LC. Do sinusoidal models of respiration accurately reflect the respiratory events of cystic fibrosis patients breathing on nebulizers? J Aerosol Med 1999;12:265-273.
22. O'Callaghan C, Clarke AR, Milner AD. Inaccurate calculation of drug output from nebulisers. Eur J Pediatr 1989;148:473-474. (Pubitemid 19049335)
23. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;8:307-310. (Pubitemid 16134762)
24. Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981;2:1137-1139. (Pubitemid 11029642)
25. Steinkamp G, Tummler B, Gappa M, Albus A, Potel J, Doring G, von der Hart H. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989;6:91-98.
26. Newman SP, Pitcairn GR, Hirst PH, Rankin L. Radionulide imaging technologies and thier use in evaluation asthma drug deposition in the lungs. Adv Drug Deliv Rev 2003;55:851-867. (Pubitemid 36776797)
27. Regnis JA, Robinson M, Bailey DL, Cook P, Hooper P, Chan H-K, Gonda I, Bye PTP. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med 1994;150:66-71. (Pubitemid 24209938)
28. Sorenson JA, Phelps ME. Problems in radiation detection and measurement. In: Physics in nuclear medicine, Ist edition. New York: Grune and Gratton Inc; 1980. pp. 208-228.
29. Geller DE, Rosenfeld M, Waltz DA, Wilmott RW, AeroDose TOBI Study Group. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery device. Chest 2003;123:28-36.
30. Coates AL, Tipples GA, Leung K, Gray M, Louca E, WHO Product Development Group for Measles Aerosol Vaccine. How many infective particles are necessary for successful mass measles immunization by aerosol? Vaccine 2006;24:1578-1585.